AIM: Considering the poor long-term success of current dietary and pharmacological interventions, we aimed to evaluate the potential effect of sodium tungstate in the treatment of grade I and II obesity (ClinicalTrials.gov identifier: NCT00555074). METHODS: Prospective, randomized, placebo-controlled, double-blind, proof-of-concept study was carried out. Following a 2-week lead-in period, 30 obese (body mass index, BMI 30.0-39.9 kg/m(2)), non-diabetic subjects were randomized to receive either sodium tungstate (100 mg bid) or placebo for 6 weeks. The primary study endpoint was the absolute change in body weight relative to the time of randomization. RESULTS: Treatment with sodium tungstate [-0.135 ± 0.268 kg (95% CI -0.686 to +0.416 kg)] was not associated with a significant weight loss compared to placebo [-0.063 ± 0.277 kg (95% CI -0.632 to +0.507 kg)] (p = 0.854). Likewise, treatment with sodium tungstate was not associated with significant changes in fat mass (DEXA), resting energy expenditure (indirect calorimetry) or caloric consumption (3-day food records). CONCLUSION: Our data do not support sodium tungstate as a pharmacological agent in the treatment of human obesity.
RCT Entities:
AIM: Considering the poor long-term success of current dietary and pharmacological interventions, we aimed to evaluate the potential effect of sodium tungstate in the treatment of grade I and II obesity (ClinicalTrials.gov identifier: NCT00555074). METHODS: Prospective, randomized, placebo-controlled, double-blind, proof-of-concept study was carried out. Following a 2-week lead-in period, 30 obese (body mass index, BMI 30.0-39.9 kg/m(2)), non-diabetic subjects were randomized to receive either sodium tungstate (100 mg bid) or placebo for 6 weeks. The primary study endpoint was the absolute change in body weight relative to the time of randomization. RESULTS: Treatment with sodium tungstate [-0.135 ± 0.268 kg (95% CI -0.686 to +0.416 kg)] was not associated with a significant weight loss compared to placebo [-0.063 ± 0.277 kg (95% CI -0.632 to +0.507 kg)] (p = 0.854). Likewise, treatment with sodium tungstate was not associated with significant changes in fat mass (DEXA), resting energy expenditure (indirect calorimetry) or caloric consumption (3-day food records). CONCLUSION: Our data do not support sodium tungstate as a pharmacological agent in the treatment of humanobesity.
Authors: Rachel P Frawley; Matthew J Smith; Kimber L White; Susan A Elmore; Ron Herbert; Rebecca Moore; Lauren M Staska; Mamta Behl; Michelle J Hooth; Grace E Kissling; Dori R Germolec Journal: J Immunotoxicol Date: 2016-05-25 Impact factor: 3.000
Authors: Rebeca Fernández-Ruiz; Marc Pino; Begoña Hurtado; Pablo García de Frutos; Carolina Caballo; Ginés Escolar; Ramón Gomis; Maribel Diaz-Ricart Journal: Drug Des Devel Ther Date: 2015-05-26 Impact factor: 4.162
Authors: Ana Isabel Fernández-Mariño; Pilar Cidad; Delia Zafra; Laura Nocito; Jorge Domínguez; Aida Oliván-Viguera; Ralf Köhler; José R López-López; María Teresa Pérez-García; Miguel Ángel Valverde; Joan J Guinovart; José M Fernández-Fernández Journal: PLoS One Date: 2015-02-06 Impact factor: 3.240